TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05451017
Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition
Normalized name: 17-hydroxy-19-nor-17-α-pregn-4-en-20-yn-3-one
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose of 1 mg AEF0117 in fasting condition
Study: NCT04904341
Drug: Cerebrolysin
Normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neuroprotection treatment
Study: NCT04827810
Drug: Gamitrinib
Normalized name: Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
Study: NCT00270426
Drug: Benazepril
Normalized name: Benazepril
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01835314
Drug: Stiripentol
Normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
Study: NCT06217848
Drug: Saxenda
Normalized name: Saxenda
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide_obesity) starting at 0.6 mg qd. Increase by 0.6 mg qd at weekly intervals to 1.2 mg qd in week 2, 1.8 mg qd in week 3, 2.4 mg qd in week 4, 3.0 mg qd in week 5, and maintain for 8 weeks at a maximally tolerated dose within 3.0 mg starting in week 5. If the subject's response to treatment does not allow for escalation to the planned dose, subjects will inject an adaptive maximally tolerated dose within the planned dose at each cycle. Total duration of Saxenda treatment is 12 weeks.
Study: NCT06350006
Drug: SHR-A1904; Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
Study: NCT06350006
Drug: SHR-A1904; CAPOX; Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)
Study: NCT03843892
Drug: OFEV
Normalized name: Ofev
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: twice daily
Study: NCT05309902
Drug: Soticlestat
Normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soticlestat tablet.
Study: NCT05309902
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin over-encapsulated tablet.
Study: NCT04683159
Drug: Brimonidine Tartrate 0.15% Oph Soln
Normalized name: BRIMONIDINE TARTRATE 0.15% OPH SOLN
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery
Study: NCT04683159
Drug: Brimonidine Tartrate 0.025% Oph Soln
Normalized name: BRIMONIDINE TARTRATE 0.025% OPH SOLN
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery
Study: NCT04347135
Drug: F-18 FES
Normalized name: F-18 Fes
DrugBank: Fluoroestradiol F-18 (DB15690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-18 FES PET/MRI for detection of endometriosis.
Study: NCT05976802
Drug: High dose budesonide rectal foam
Normalized name: budesonide Rectal Foam
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Twice a day for 2 weeks, then once a day for 4 weeks
Study: NCT05976802
Drug: Low dose budesonide rectal foam
Normalized name: budesonide Rectal Foam
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Twice a day for 2 weeks, then once a day for 4 weeks
Study: NCT05565391
Drug: Elranatamab
Normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCMA-CD3 bispecific antibody
Study: NCT05740891
Drug: BCMA CAR-T cells injection
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous hematopoietic stem cell transplantation combined with BCMA CAR-T cells
Study: NCT06506292
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab:1200 mg, iv, d1
Study: NCT06584240
Drug: Sequence 2
Normalized name: ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE
DrugBank: Susoctocog alfa (DB11606)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Single treatment, intramuscularly injected. The total injection 200-250U.
Study: NCT06584240
Drug: Sequence 3
Normalized name: ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE
DrugBank: Susoctocog alfa (DB11606)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Single treatment, intramuscularly injected. The total injection 350-400U.
Study: NCT06584240
Drug: Sequence 4
Normalized name: ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE
DrugBank: Susoctocog alfa (DB11606)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Single treatment, intramuscularly injected. The total injection ≤400U.
Study: NCT05932472
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin at currently prescribed dose
Study: NCT04678830
Drug: Leronlimab (700mg)
Normalized name: Leronlimab
DrugBank: Leronlimab (DB05941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Study: NCT04789915
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add on treatment with memantine to aripiprazole.
Study: NCT05949203
Drug: Cabotegravir Injection
Normalized name: cabotegravir Injection
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of HIV pre-exposure prophylaxis with cabotegravir 600 mg/3mL extended release injectable suspension every other month.
Study: NCT05779007
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone
Study: NCT05779007
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib
Study: NCT04642391
Drug: Cosyntropin
Normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
Study: NCT06154707
Drug: Denosumab Injection
Normalized name: denosumab Injection
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
Study: NCT05068427
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20mg or 30mg orally twice per week(BIW)
Study: NCT05068427
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg subcutaneous infusions every 4 weeks
Study: NCT04823442
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
Study: NCT04823442
Drug: Bisoprolol Fumarate
Normalized name: Bisoprolol Fumarate
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a single dose of 10 mg (2 tablets of 5 mg)
Study: NCT06426303
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.
Study: NCT06223685
Drug: Rifaximin 200 MG
Normalized name: rifAXIMin 200 MG
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage 3x2 tablets per day 14 days
Study: NCT04334993
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with high risk disease features after 2 induction blocks as defined per protocol will be treated with CNS directed block followed by up to 2 cycles of blinatumomab (for B-cell ALL) followed by allogeneic stem cell transplantation.
Study: NCT04865419
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole film-coated tablet will be administered orally.
Study: NCT04991974
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community.
Study: NCT00001994
Drug: Atovaquone
Normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06315400
Drug: Ingavirin®
DrugBank: Ingavirin (DB11944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day for 5 days
Study: NCT05097781
Drug: PD-1 blocking antibody
Normalized name: Humanized pd-1 blocking antibody hx-008
DrugBank: Pucotenlimab (DB17552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
Study: NCT06345560
Drug: Drospirenone
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg tablet once daily
Study: NCT06553248
Drug: GZR4
Normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
Study: NCT06553248
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered once daily subcutaneously (s.c., under the skin) for 6 weeks
Study: NCT05126329
Drug: amcenestrant
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet for oral use
Study: NCT06631976
Drug: Nerve block with 4ml of 2% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nerve block with 4ml of 2% lidocaine around the suprascapular nerve
Study: NCT06009861
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 200 mg Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
Study: NCT06009861
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 260 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
Study: NCT06009861
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 60-75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks
Study: NCT06629051
Drug: Berberine Hydrochloride
Normalized name: Berberine Hydrochloride
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: post-intervention of berberine
Study: NCT05632068
Drug: Xian-Hua-Cha
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zizyphus jujuba Mill., Nelumbo nucifera Gaertn, Citrus reticulata Blanco, Rosa rugosa Thunb., Cassia obtusifolia L., Stevioside, resistant starch, and water
Study: NCT05922124
Drug: Cefiderocol
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Test drug regimen
Study: NCT05922124
Drug: Ampicillin-sulbactam
Normalized name: ampicillin-sulbactam
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synergistic combination
Study: NCT05922124
Drug: Colistin
Normalized name: Colistin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Historical comparator
Study: NCT05922124
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Historical comparator synergistic combination
Study: NCT05230901
Drug: Dihydralazine
Normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)
Study: NCT05306587
Drug: Darzalex
Normalized name: Darzalex
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
Study: NCT04694248
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
Study: NCT04694248
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
Study: NCT05359224
Drug: Prasugrel group
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given prasugrel 5mg once. And aspirin 100mg and prasugrel 5mg will be maintained for 30 days.
Study: NCT05359224
Drug: Clopidogrel group
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prescribe the drugs according to the assigned group, and take them 5 days before the procedure. Perform platelet function test (VerifyNow assay; Accumetrics, San Diego, California) one day before the procedure to check the P2Y12 reaction reactivity. And the hyporesponsive group patient is given pletaal 100mg once. And aspirin 100mg and clopidogrel 75mg mg will be maintained for 30 days.
Study: NCT04977128
Drug: 89Zr-KN035
Normalized name: 89ZR-BEVACIZUMAB
DrugBank: Bevacizumab zirconium Zr-89 (DB14907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
Study: NCT04731051
Drug: HCQ01
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
Study: NCT05919888
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied to skin incision.
Study: NCT00001011
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000442
Drug: naltrexone (Revia)
Normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06360042
Drug: Adebrelimab plus Apatinib
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
Study: NCT06360042
Drug: Adebrelimab plus Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
Study: NCT06360042
Drug: Camrelizumab plus Apatinib
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
Study: NCT04628572
Drug: Ceftazidime-avibactam
Normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-Interventional Study
Study: NCT06283134
Drug: toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioTTT001 in combination with toripalimab and regorafenib period: toripalimab 80mg intravenous D1 and D15, 4 weeks per cycle.
Study: NCT06283134
Drug: regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BioTTT001 in combination with toripalimab and regorafenib period: regorafenib 80 mg oral administration, D1-D21, 4 weeks per cycle.
Study: NCT05246371
Drug: Propofol, dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive maintenance of general anesthesia by TIVA using combination of propofol and dexmedetomidine.
Study: NCT05246371
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive maintenance of general anesthesia by desflurane.
Study: NCT05318573
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment at 200 mg pembrolizumab, administered intravenously (IV) on Day 1 of each 21-day cycle prior to infusion of FF-10832
Study: NCT05318573
Drug: FF-10832
Normalized name: FF-10501
DrugBank: FF-10501-01 (DB17554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following administration of pembrolizumab, FF-10832 Gemcitabine Liposome Injection, 40 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle
Study: NCT06447415
Drug: HRS-7450
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-7450 Injection
Study: NCT06447415
Drug: 0.9% sodium chloride injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection
Study: NCT06367517
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks
Study: NCT06310616
Drug: Loestrin
Normalized name: Lo Loestrin Fe
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loestrin will be administered.
Study: NCT04699383
Drug: Sodium Stibogluconate with allopurinol
Normalized name: sodium stibogluconate
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine administration of SSG/allopurinol combination treatment, from 1-5 cycles
Study: NCT05193604
Drug: Anlotinib Hydrochloride Capsule
Normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study: NCT05193604
Drug: Gemcitabine hydrochloride for injection
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy medicine for metastatic pancreatic cancer
Study: NCT05193604
Drug: Paclitaxel for injection (albumin bound)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy medicine for metastatic pancreatic cancer
Study: NCT04970654
Drug: somapacitan
Normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Somapacitan (0.16 mg/kg/week) will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
Study: NCT05302804
Drug: Menthol Gel
Normalized name: MENTHOL GEL,TOP
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% menthol gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
Study: NCT05302804
Drug: Control Gel
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypoallergenic gel applied from shoulder to wrist and mid thigh to ankle, 30 minute treadmill walk (3.5 mph at 5% grade at 38°C, 60% relative humidity)
Study: NCT06134388
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine is an anti-inflammatory drug that is indicated for treatment of ulcerative colitis and rheumatoid arthritis.
Study: NCT04246762
Drug: Olokizumab
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution for subcutaneous (SC) injection, 128 mg (0.8 mL injection)
Study: NCT04246762
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 20 mg, oral
Study: NCT04246762
Drug: Warfarin+ Vitamin K
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin -Tablets 10 mg (containing 5 mg S-warfarin), oral. Vitamin K - solution for intravenous injection, 10 mg/mL ampoule, orally.
Study: NCT04246762
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Syrup, 2 mg/mL, oral
Study: NCT04643405
Drug: APG-1387 for Injection
Normalized name: APGA
DrugBank: APG-1387 (DB16095)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG1387 will be administered IV days 1， 8, 15 and 22 of a 28 day cycle.
Study: NCT04643405
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m\^2 will be administered IV days 1, 8, and 15 of a 28 day cycle.